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AbsTRACT
background Achilles tendinopathy is a common 
problem, but its exact aetiology remains unclear.
Objective To evaluate the association between 
potential clinical risk factors and Achilles tendinopathy.
Design Systematic review.
Data sources The databases Embase, MEDLINE Ovid, 
Web of Science, Cochrane Library and Google Scholar 
were searched up to February 2018.
Eligibility criteria To answer our research question, 
cohort studies investigating risk factors for Achilles 
tendinopathy in humans were included. We restricted our 
search to potential clinical risk factors (imaging studies 
were excluded).
Results We included 10 cohort studies, all with a high 
risk of bias, from 5111 publications identified. There is 
limited evidence for nine risk factors: (1) prior lower limb 
tendinopathy or fracture, (2) use of ofloxacin (quinolone) 
antibiotics, (3) an increased time between heart 
transplantation and initiation of quinolone treatment for 
infectious disease, (4) moderate alcohol use, (5) training 
during cold weather, (6) decreased isokinetic plantar 
flexor strength, (7) abnormal gait pattern with decreased 
forward progression of propulsion, (8) more lateral foot 
roll-over at the forefoot flat phase and (9) creatinine 
clearance of <60 mL/min in heart transplant patients. 
Twenty-six other putative risk factors were not associated 
with Achilles tendinopathy, including being overweight, 
static foot posture and physical activity level.
Conclusion From an ocean of studies with high levels 
of bias, we extracted nine clinical risk factors that 
may increase a person’s risk of Achilles tendinopathy. 
Clinicians may consider ofloxacin use, alcohol 
consumption and a reduced plantar flexor strength 
as modifiable risk factors when treating patients with 
Achilles tendinopathy.
Trial registration number CRD42017053258.
InTRODuCTIOn
The Achilles tendon is the largest and strongest 
tendon in the human body, yet it is prone to injury 
such as tendinopathy. The presence of Achilles 
tendon pain, swelling and an impaired load-
bearing capacity indicate Achilles tendinopathy 
(AT).1–3 From a clinical perspective, insertional 
and midportion AT should be distinguished since 
these are two separate entities with different treat-
ment approaches.4 AT is most frequently seen in 
elite running athletes, with a lifetime risk of 52%.5 
It should, however, be noted that one-third of all 
patients with AT have a sedentary lifestyle.6 This 
emphasises that there is probably a broad spectrum 
of potential risk factors for AT, yet the exact aeti-
ology remains uncertain.7 
Over the last decades, various determinants have 
been proposed as risk factors in the development 
of AT. A recent systematic review examined risk 
factors for AT with a primary focus on genetic 
aspects.8 They found that certain genetic determi-
nants may contribute to the development of AT, 
such as genetic contributors to collagen structure 
formation and tendon homeostasis. However, 
results were ambiguous due to the methodology in 
the publications included. These publications had 
mixed study designs, and the number of non-ge-
netic clinical risk factors was limited. Therefore, 
there is a need to evaluate clinical risk factors in 
the development of AT with an extensive literature 
search and robust methodological design.
In this study, we systematically review the liter-
ature regarding the potential clinical risk factors 
that have been investigated for AT. This provides 
the level of evidence for all known clinical risk 
factors to inform future prevention and treatment 
strategies.
METhODs
Protocol and registration
The protocol for this systematic review was prospec-
tively registered in the international PROSPERO 
database. Protocol details can be accessed via http://
www. crd. york. ac. uk/ PROSPERO/ display_ record. 
asp? ID= CRD42017053258. A protocol revision 
was performed in July 2017 from midportion AT 
as site of injury to AT in general (insertional and 
midportion AT combined). This was done as we 
observed during data extraction that a substantial 
number of publications did not specify the specific 
location.
Eligibility criteria
Publications were eligible for inclusion when 
there was: (1) a potential risk factor investigated 
in relation to AT and (2) a diagnosis of AT based 
on clinical findings (local pain and impaired load-
bearing capacity). We restricted our selection to 
prospective and retrospective cohort studies written 
in English. A determinant was considered to be a 
potential clinical risk factor if no extensive exam-
ination (eg, biopsies) had been performed. Publica-
tions were excluded if there was: (A) no adequate 
control group (eg, contralateral Achilles tendon), 
(B) a preclinical study design or (C) an imaging 
study design (eg, potential risk factors derived from 
MRI or ultrasound examinations). Imaging studies 
were excluded, since these are regularly not directly 
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Table 1 Risk of bias assessment tool
Criteria Response Yes no/not reported
1. A clearly stated aim  ► Did they have a ‘study question’ or ‘main aim’ or ‘objective’? □ □
 ► The question addressed should be precise and relevant in light of available 
literature.
□ □
 ► To be scored adequate the aim of the study should be coherent with the 
‘Introduction’ of the paper.
□ □
2. Inclusion of consecutive patients  ► Did the authors say: ‘consecutive patients’ or ‘all patients during period from … 
to….’ or ‘all patients fulfilling the inclusion criteria’?
□ □
3. A description of inclusion and exclusion 
criteria
 ► Did the authors report the inclusion and exclusion criteria? □ □
4. Inclusion of patients  ► Did the authors report how many eligible patients agreed to participate (ie, 
gave consent)?
□ □
5. Prospective collection of data. Data 
were collected according to a protocol 
established before the beginning of the 
study
 ► Did they say ‘prospective’, ‘retrospective’ or ‘follow- up’? The study is not 
prospective when it is a chart review, database review, clinical guideline, or 
practical summaries.
□ □
6. Outcome measures  ► Did they report the association between the potential risk factors and 
manifestation of Achilles tendinopathy as outcome? The valid outcome measure 
for Achilles tendinopathy is clinical examination.
□ □
7. unbiased assessment of the study outcome 
and potential risk factors
 ► To be judged as adequate, the following two aspects had to be positive:
 – Outcome and potential risk factors had to be measured independently.
 – The outcome and potential risk factors for both cases and controls had to be 
assessed in the same way.
□ □
8. Were the determinant measures used 
accurate (valid and reliable)?
 ► For studies where the determinant measures are shown to be valid and reliable, 
the question should be answered adequate. For studies that refer to other work 
that demonstrates the determinant measures are accurate, the question should 
be answered as adequate.
□ □
9. Loss to follow-up  ► To be judged as adequate, the following two aspects had to be positive:
 – Did they report the losses to follow-up?
 – Loss to follow-up was <20%.
□ □
10. Adequate statistical analyses  ► To be judged as adequate the following two aspects had to be positive:
 – There must be a description of the relationship between the potential risk 
factors and Achilles tendinopathy (with information about the statistical 
significance).
 – Was there adjustment for possible confounders (age, sex and body mass 
index) by multivariate analysis?
□ □
For each methodological criterion that is met 1 point is given. If the criterion was not met, zero points were given. Publications were considered to be of low risk of bias if: (1) a 
total score of at least 6 points was given and (2) 1 point was given to questions 6, 7, 8 and 10 (marked with the grey columns).
available in the sports physician consultation room. For an over-
view of imaging, we refer to a recent systematic review.9
We also aimed to identify potential novel risk factors as 
secondary outcome measure by including cross-sectional studies. 
While the level of evidence from cross-sectional studies is lower 
than that from cohort studies, they might identify interesting 
factors to explore in future research.
Literature search strategy and information sources
We conducted a sensitive search strategy for multiple databases 
with the assistance of a medical librarian (W M Bramer). The 
following databases were searched up to 12 February 2018: 
Embase, MEDLINE Ovid, Web of Science, Cochrane Library 
and Google Scholar. The search strategy is shown in online 
supplementary appendix 1.
study selection and data extraction
Titles and abstracts were screened by two independent reviewers 
(ACvdV and RJdV) to identify eligible publications. Disagree-
ments were solved by consensus, with the involvement of a 
third review author (EHGO) if necessary. Data extraction 
was performed by one author (ACvdV), and a data check was 
performed by a second author (SJB) for 100% of the primary 
outcomes and for 20% of the other data. This has been shown 
to be a methodologically sound procedure.10 The potential risk 
factors were extracted and grouped into patient characteristics 
(modifiable and non-modifiable), biomechanical factors, pre-ex-
isting diseases, medication and training factors. AT subgroup 
analysis results are presented in case subgroup analyses were 
performed in studies describing associations for multiple inju-
ries. If multiple populations with AT were assessed in a single 
publication, only combined results are presented.
Risk of bias assessment
Two reviewers (ACvdV and SJB) independently assessed the 
methodological quality of all included prospective (level of 
evidence II) and retrospective cohort studies (level of evidence 
III). No risk of bias assessment was performed for cross-sectional 
studies (level of evidence IV), since these studies are considered 
to be of high risk of bias for the purpose of this review.
To assess risk of bias, we used a standardised set of criteria 
based on modified questions of existing quality assessment tools 
(table 1).11–13 This tool has previously been used in a systematic 
review on risk factors for Achilles tendon rupture.14 If a crite-
rion was met, one point was given. No points were given if the 
criterion was not met or when it was unclear if the specific crite-
rion was met. A maximum score of 10 points could be obtained. 
Publications were considered to be of low risk of bias if: (1) a 
total score of 6 points or more was given and (2) 1 point was 
given to criteria 6, 7, 8 and 10.14 4300.7802.430. Protected by copyright.
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5111 publications identified through
database searching.
3225 publications after duplicates were
removed
109 full-text publications assessed for
eligibility
Prospective cohort studies: 8
Retrospective cohort studies: 2
Cross-sectional case-control studies: 45
3116 publications excluded on the
basis of title and abstract
54 publications did not fulfill the inclusion criteria:
Diagnosis not based on clinical findings: 3
No adequate control group: 3
Mixed injury without Achilles tendinopathy subgroup
analyses: 24
Imaging study: 9
Previous Achilles tendinopathy with currently no
symptoms: 3
Conference abstract or letter: 10
Case serie: 1
Test not clinically available: 1
55 publications eligible for inclusion
EMBASE: 1770
MEDLINE OVID: 1484
Web of Science: 1606
Cochrane Central: 51
Google Scholar: 200
Figure 1 PRISMA 2009 flow diagram of study selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.  
Data synthesis
A subgroup analysis was initially planned for insertional and 
midportion AT; however, we revised the PROSPERO protocol 
(revision date 20 July 2017) because a substantial number of 
publications did not specify the AT location. Homogeneity of 
the data was evaluated, and if data could not be pooled because 
of heterogeneity, a best evidence synthesis based on the study of 
van Tulder et al was carried out for each potential risk factor.15
1. Strong evidence: ≥2 studies with high quality and generally 
consistent findings in all studies (≥75% of the studies report-
ed consistent findings).
2. Moderate evidence: one high-quality study and ≥2 low-qual-
ity studies and generally consistent results (≥75% of the 
studies reported consistent findings).
3. Limited evidence: generally consistent findings 
in ≥1 low-quality study (≥75% of the studies reported con-
sistent findings).
4. Conflicting evidence: <75% of the studies reporting consist-
ent findings.
5. No evidence: no studies could be found.
REsuLTs
study selection
We identified 5111 potentially relevant publications, and 
after removing duplicates, 3225 remained. After screening 
title and abstract, we assessed 109 publications in full text. 
Fifty-four publications were excluded for different reasons 
after full-text evaluation, as shown in the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow chart (figure 1). We included the remaining 55 publica-
tions for analysis.
Characteristics of the included publications
We included eight prospective cohort studies16–23 and two 
retrospective cohort studies.24 25 Additionally, 45 cross-sec-
tional studies were included.5 26–69 The characteristics and 
main findings of the included studies are summarised in 
table 2 for the cohort studies and online supplementary 
appendix 2 for the cross-sectional studies.
Of the 10 cohort studies, five studies included only partic-
ipants with midportion AT and five studies did not specify 
the AT location. Sample sizes of the included cohort studies 
ranged from 69 to 80 106 participants (median 285) with the 
number of AT cases ranging from 5 to 450 (median 18). Mean 
age ranged from 18 years old to 59 years old (median 21). 
This relatively young median age was caused by the profes-
sion of most of the populations investigated (military recruits 
in five studies, students in one study). There was a greater 
proportion of male participants in seven cohort studies, 
compared with two studies in which there was a greater 4300.7802.430. Protected by copyright.
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Table 3 Risk of bias assessment scores of the 10 included cohort studies
study
Criteria
Total score
Risk of 
bias1 2 3 4 5 6 7 8 9 10
Barge-
Caballero et 
al24
1 1 1 0 0 0 0 1 0 1 5 High 
Hein et al20 1 0 1 1 1 0 0 0 0 0 4 High
Kaufman et 
al21
1 1 0 1 1 1 1 0 0 0 5 High
Mahieu et 
al16
0 1 0 1 1 1 1 0 0 1 6 High
Milgrom et 
al22
0 0 0 1 1 1 0 0 0 0 3 High
Owens et 
al17
1 1 0 1 1 0 1 1 0 0 6 High
Rabin et al18 1 1 1 1 1 1 1 0 1 1 9 High
Van der 
Linden et 
al25
1 1 1 0 1 0 1 1 0 0 6 High
Van Ginckel 
et al19
1 0 1 1 1 1 1 0 0 1 7 High
Wezenbeek 
et al23
1 1 1 0 1 1 0 1 0 1 7 High
Outcomes of the risk of bias assessment tool as presented in table 1. Publications were considered to be of low risk of bias if: (1) a total score of at least 6 points was given and 
(2) 1 point was given to questions 6, 7, 8 and 10 (marked with the grey columns).
proportion of female participants (median percentage males 
78%). Data regarding the number of participants, mean age 
or sex was incomplete in two studies. The follow-up period 
for the prospective cohort studies ranged from 6 weeks to 2 
years (median 39 weeks).
Of the 45 cross-sectional studies, 15 studies included only 
participants with midportion AT, one study included patients 
with insertional AT and 29 studies did not specify the AT 
location. Sample sizes ranged from 20 to 57 725 participants 
(median 201).
Risk of bias assessment
All 10 cohort studies were considered to be of high risk of 
bias according to the predefined criteria (tables 1 and 3). 
Seven cohort studies scored six points or higher; however, 
they were lacking clinical examination as valid outcome 
(two studies), a valid and reliable determinant measure (four 
studies), an unbiased assessment of the study outcome (one 
study) and/or adequate statistical analyses (three studies). 
As a result, at best, a limited evidence for the association 
between the potential risk factor and tendinopathy could be 
detected. Results of the best evidence synthesis are presented 
in table 4.
Risk factors
Patient characteristics (non-modifiable)
Age
There is conflicting evidence that age affects the risk for AT. 
One cohort study reported in 2013 that a birth year of 1980 
or later is associated with a decreased risk for AT.17 Two 
cohort studies showed no association.19 24
Sex
There is conflicting evidence that sex affects the risk for AT. 
One cohort study reported that being female is associated 
with AT.23 No association was demonstrated in two cohort 
studies.17 24
Ethnicity
There is limited evidence that ethnicity does not affect the risk 
for AT. One cohort study reported no increased risk for white 
(non-Hispanic), black (non-Hispanic) or other ethnicity.17
Height
There is limited evidence that height does not affect the risk for AT. 
No association was found in three cohort studies.16 19 22 One cohort 
study reported an increased height in patients with AT.23
Prior lower limb tendinopathy or fracture
There is limited evidence that a prior lower limb tendinopathy or 
fracture increases the risk for AT. One cohort study reported that a 
prior lower limb tendinopathy (plantar fascia, Achilles or patellar) 
or fracture (regardless side of injury) is associated with AT.17
Patient characteristics (modifiable)
Body mass index (BMI) and body weight
There is limited evidence that BMI or body weight do not affect 
the risk for AT. No association was found in five cohort studies for 
BMI16 18 19 22 23 and in three cohort studies for body weight.16 19 22 
One cohort study found that being overweight (BMI ≥25.0) and 
obesity (BMI ≥30.0) are associated with AT.17 Another cohort study 
found that body weight is increased in people who develop AT.23
Alcohol use
There is limited evidence that moderate alcohol use increases the 
risk for AT. Moderate alcohol use was defined as 7–13 units per 
week for men and 4–6 units per week for women. One cohort study 
reported that moderate alcohol use is associated with AT compared 
with no alcohol use. No association was found for light alcohol use 
or heavy alcohol use compared with no alcohol use.17
Smoking
There is limited evidence that smoking is not associated with AT 
based on one cohort study.17
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Table 4 Potential risk factors investigated in the 10 cohort studies as potential risk factor for Achilles tendinopathy
Potential risk factors study (first author and reference number) best evidence synthesis
Patient characteristics (non-modifiable)
Age Barge-Caballero =24, Owens birth year >1980 ↓,17 Van 
Ginckel =19
Conflicting evidence
Sex Barge-Caballero =24, Owens =17 Wezenbeek female ↑23 Conflicting evidence
Ethnicity Owens =17 Limited evidence for no association
Height Mahieu =,16 Milgrom =,22 Van Ginckel =,19 Wezenbeek ↑23 Limited evidence for no association
Prior lower limb tendinopathy or fracture Owens ↑17 Limited evidence for positive association
Patient characteristics (modifiable)
Body mass index Owens BMI >25.0 ↑,17 Mahieu =,16 Milgrom =,22 
Rabin =,18 Van Ginckel =,19 Wezenbeek =23
Limited evidence for no association
Body weight Mahieu =,18 Milgrom =,22 Van Ginckel =,23 Wezenbeek ↑23 Limited evidence for no association
Alcohol use Owens 7–13 units per week for men, 4–6 units per week 
for women ↑,17 Owens 14+ units per week for men, 
7+ units per week for women =17
Limited evidence for positive association (moderate 
alcohol use)
Smoking Owens =17 Limited evidence for no association
Physical activity level and performance Mahieu physical activity level =,16 Van Ginckel physical 
activity level=,19 Milgrom physical activity performance 
(2 km run and maximum number of chin-ups and sit-
ups) =,22 Wezenbeek =23
Limited evidence for no association
biomechanical factors
Shoe type Milgrom =22 Limited evidence for no association
Leg dominance Wezenbeek =23 Limited evidence for no association
Limited non-weight-bearing ankle dorsiflexion with knee 
extended
Kaufman <11.5° ↑,21 Mahieu =16 Conflicting evidence
Increased non-weight-bearing ankle dorsiflexion with the 
knee bent
Mahieu =,16 Rabin ↓,18 Kaufman =21 Conflicting evidence
Hindfoot inversion Kaufman =21 Limited evidence for no association
Hindfoot eversion Kaufman =21 Limited evidence for no association
Static arch index of the foot Kaufman =,21 Milgrom =22 Limited evidence for no association
Dynamic arch index of the foot Kaufman =21 Limited evidence for no association
Pronated foot posture Wezenbeek =23 Limited evidence for no association
Increase in isokinetic plantar flexor strength at 30° (low 
velocity)
Mahieu ↓16 Limited evidence for protective association
Explosive gastrocnemius-soleus muscle strength Mahieu =16 Limited evidence for no association
External rotation of the hip Milgrom =22 Limited evidence for no association
Tibial intercondylar distance Milgrom =22 Limited evidence for no association
lower extremity quality of movement test Rabin =18 Limited evidence for no association
Increased total displacement of the Y-component of the 
centre of the centre of force
Van Ginckel ↓19 Limited evidence for protective association
Increased medial directed force distribution Van Ginckel ↓19 Limited evidence for protective association
Pre-existing diseases
Renal dysfunction (creatinine clearance <60 mL/min) Barge-Caballero ↑24 Limited evidence for positive association
increased time between heart transplantation and 
initiation of quinolone treatment for infectious disease
Barge-Caballero ↑24 Limited evidence for positive association
Medication
Fluoroquinolones as group Van der Linden =25 Limited evidence for no association
Levofloxacin Barge-Caballero =24 Limited evidence for no association
Ofloxacin Van der Linden ↑25 Limited evidence for positive association
Ciprofloxacin Van der Linden =25 Limited evidence for no association
Norfloxacin Van der Linden =25 Limited evidence for no association
Daily prednisone dose Barge-Caballero =24 Limited evidence for no association
Training factors
Training in the winter season Milgrom ↑22 Limited evidence for positive association
Associations found in this systematic review are marked with the grey columns. 
=no association; ↑ positive association; ↓protective association.
Physical activity level, physical activity performance and hours of 
sports participation
There is limited evidence that physical activity level, physical 
activity performance or hours of sports participation do not 
affect the risk for AT. Two cohort studies found no association 
between the physical activity level measured with the Baecke 
questionnaire and AT.16 19 One cohort study found no associ-
ation between the physical activity performance (2 km run and 
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maximum number of chin-ups and sit-ups) and AT.22 Another 
cohort study found no differences in hours of sports participa-
tion between patients with AT and unaffected controls.23
Biomechanical factors
Shoe type
There is limited evidence that the type of shoes is not associated with 
AT. One cohort study found no difference in AT incidence between 
modified basketball shoes and standard lightweight infantry boots.22
Leg dominance
There is limited evidence that leg dominance is not associated 
with AT based on one cohort study.23
Static and dynamic properties of the foot
There is limited evidence that hindfoot inversion, hindfoot ever-
sion, the static arch index of the foot, the dynamic arch index of 
the foot and a pronated foot posture do not increase the risk for 
AT. One cohort study reported that hindfoot inversion, hindfoot 
eversion, the static arch index of the foot and the dynamic arch 
index of the foot are not associated with AT.21 Another cohort 
study also found no association between the static arch index of 
the foot and AT.22 The third cohort study found no association 
between a pronated foot posture and AT.23
Static and dynamic properties of the ankle
There is conflicting evidence that a decreased non-weight-
bearing ankle dorsiflexion is associated with AT. One cohort 
study found that a limited ankle dorsiflexion (<11.5°) with the 
knee extended is associated with AT compared with a normal 
ankle dorsiflexion (11–15°).21 Another cohort study evalu-
ating ankle dorsiflexion with the knee extended did not show 
an association.16 One cohort study found that a one degree 
increase in ankle dorsiflexion with the knee bent is associated 
with a decreased risk for AT.18 Two cohort studies evaluating 
ankle dorsiflexion with the knee bent demonstrated no associ-
ation.16 21
Limited evidence was found that an increased isokinetic 
plantar flexor strength at 30°/s (low velocity) is associated with a 
decreased risk for AT. No association between explosive gastroc-
nemius-soleus muscle strength (measured with the standing 
broad jump test) and AT was found in this study.16
Static and dynamic properties of the knee
There is limited evidence that the tibial intercondylar distance is 
not associated with AT based on one cohort study.22
Static and dynamic properties of the hip
There is limited evidence that the amount of external rotation 
of the hip is not associated with AT based on one cohort study.22
Gait analysis
There is limited evidence that an abnormal gait pattern with 
decreased forward progression of the propulsion and a more 
lateral foot roll-over at the forefoot flat phase are associated 
with AT. One cohort study reported a protective association per 
millimetre increase in total displacement of the Y-component of 
the centre of force. This cohort study also reported a decreased 
risk for AT if the mediolateral pressure distribution ratio under-
neath the forefoot at forefoot flat phase increased.19 No associa-
tions were found in another cohort study for the lower extremity 
quality of movement test.18
Pre-existing diseases
Renal dysfunction
There is limited evidence that a creatinine clearance <60 mL/
min is associated with AT in heart transplant patients. One 
cohort study reported an increased risk to develop AT in this 
specific group compared with heart transplant patients with a 
creatinine clearance ≥60 mL/min.24
Heart diseases
There is limited evidence that an increased time (in years) 
between heart transplantation and initiation of quinolone treat-
ment for infectious disease is associated with AT. One cohort 
study described this association.24 This outcome was solely 
investigated in heart transplant patients that all received quino-
lone treatment. Therefore, heart transplantation and quinolone 
treatment cannot be evaluated as individual risk factors in this 
cohort study.
Medication
Fluoroquinolones
There is limited evidence that the use of ofloxacin is associated 
with AT. One cohort study found an increased risk to develop 
AT when using ofloxacin compared with other antibiotic drugs 
(without fluoroquinolones).25 This cohort study found no asso-
ciations for fluoroquinolones as a group, ciprofloxacin and 
norfloxacin. Another cohort study found no association between 
levofloxacin use and AT specifically in heart transplant patients 
compared with no use of levofloxacin.24
Corticosteroids
There is limited evidence that daily oral prednisone dose is not 
associated with AT based on one cohort study.24
Training factors
Training season
There is limited evidence that training during cold weather is 
associated with AT. One cohort study found that the incidence 
of AT increased during recruit winter training compared with 
summer training.22
Potential risk factors evaluated in cross-sectional studies
In the 45 cross-sectional studies, 296 risk factors were investi-
gated. One hundred and fifteen associations were found, mostly 
consisting of biomechanical factors (56 associations) or genetic 
factors (30 associations). All data are presented in online supple-
mentary appendix 2.
DIsCussIOn
summary of main findings
This is the first high-quality systematic review of clinical risk 
factors for Achilles tendinopathy. We identified 10 cohort studies, 
all of which had a high risk of bias and 45 cross-sectional studies.
There is limited evidence for the following nine risk factors: (1) 
prior lower limb tendinopathy or fracture, (2) use of ofloxacin anti-
biotics, (3) increased time between heart transplantation and initi-
ation of quinolone treatment for infectious disease, (4) moderate 
alcohol use, (5) training during cold weather, (6) decreased 
isokinetic plantar flexor strength, (7) abnormal gait pattern with 
decreased forward progression of propulsion, (8) more lateral 
foot-roll over at the forefoot flat phase and (9) a creatinine clear-
ance of <60 mL/min in heart transplant patients.16 17 19 22 24 25
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Although other potential risk factors such as body weight or 
BMI, static foot posture measurements and physical activity level 
are often said to be risk factors in clinical practice, there is currently 
no scientific evidence that they are associated with AT.16–19 21–24 70
Clinical implications
Our systematic review indicates that for AT prevention and treat-
ment, the advice to patients might include: (1) to reduce the use of 
alcohol to less than 7 units per week for men and less than 4 units 
for women, (2) to avoid the use of ofloxacin if alternatives are 
available and (3) to improve plantar flexor strength by performing 
strengthening exercises of the calf muscles.16 17 25
Whether these interventions will be effective is unknown. For 
example, calf muscle exercises seem a plausible preventive interven-
tion as decreased plantar flexor strength is a risk factor. However, 
eccentric calf muscle exercises did not decrease AT incidence in 
soccer players in a randomised trial.71 Further research is needed 
before we can state whether the logical interventions work or not.
Abnormal gait pattern with decreased forward progression of 
the propulsion and a more lateral foot roll-over at the forefoot flat 
phase were found to be risk factors for AT in novice runners. Van 
Ginckel et al stated that more research is needed to confirm these 
findings, since this gait pattern with a decreased forward progres-
sion might be commonly used in well-trained athletes to improve 
gait economy.19 72 Since the gait pattern was determined barefoot, 
it is also not known whether these findings can be extrapolated 
to the running population, as running shoes might alter running 
gait.19 Biomechanical characteristics in AT are discussed in more 
detail in a recent systematic review.73
Previous research showed the relationship between BMI, body 
weight or waist circumference and tendon pathology.74 The 
hypothesis of this relationship is primarily based on the fact that 
the absolute tendon load is increased and that increased cytokine 
levels (Prostaglandin E2, tumor necrosis factor-α and Leukot-
riene B4) cause low-grade inflammation in obese individuals.75 76 
In our systematic review, we were not able to find an association 
between being overweight and AT.16–19 22 23 It should be noted that 
more than half of the cohort studies that investigated BMI as a risk 
factor were in adolescent populations, in which being overweight 
is less common.77 Arnoczky and colleagues hypothesised based on 
an animal model that being underweight is associated with AT, as 
a consequence of a catabolic state causing a decreased collagen 
production.78 This could lead to a U-shaped relationship for the 
BMI and AT, making it less likely that an association be found.79 
More cohort studies are needed in heterogeneous populations.
Another striking finding is the limited evidence for the absence 
of an association between physical activity level and AT. Inconclu-
sive results regarding physical activity level were previously also 
demonstrated in patellar tendinopathy.80 In the majority of the 
scientific literature, tendinopathy is described as ‘overuse injury’. It 
could be that ‘overuse’ or ‘physical activity level’ is not measured 
accurately enough to detect associations. It could also be hypothe-
sised that a sudden change in load is more important than the abso-
lute load that is currently being measured in studies. To date, there 
is, however, no convincing evidence that AT is a result of overuse.
Moderate alcohol use and increased time between heart trans-
plantation and initiation of quinolone treatment for infectious 
disease were potential risk factors for AT.17 24 It is hard to hypothe-
sise why these determinants are risk factors for AT. They might be 
a confounding factor, with lifestyle factors that influence AT risk. 
Another reason might be that these findings have been detected by 
chance. When a high number of analyses are performed, the chance 
of statistical significance findings increases. Adequate statistical 
methods can prevent possible coincidental findings. Another poten-
tial risk factor that is lacking a clear explanation is training during 
cold weather.22 The direct cause-effect relationship is not known, as 
the results might be influenced by temperature or type of surface. 
This particular study did not report information on the tempera-
ture or training surface during the training period. These results are 
therefore difficult to extrapolate.
Research implications
Our review showed that the majority of potential risk factors have 
only been investigated in cohort studies with a low number of cases 
(median 18 cases). Professor Roald Bahr and colleagues demon-
strated that 20–50 cases are needed to detect moderate to strong 
associations and even 200 cases to detect small to moderate asso-
ciations.81 Therefore, most studies in this review are likely to be 
underpowered to detect associations. Sample sizes in future studies 
should therefore be considered carefully. Future studies should also 
distinguish insertional from midportion AT, since these are two 
separate entities. It has been suggested that compression forces due 
to the bony prominence of the calcaneus play a role in the develop-
ment of insertional AT, while this does not occur in midportion AT.4 
Combining these entities, as occurred in most studies, is not ideal.
There are several interesting determinants found in the cross-sec-
tional studies for future research. Use of oral contraceptives and 
hormone replacement therapy were more common in patients 
suffering from AT.38 Only one research group investigated these 
factors; therefore, more research is needed to confirm these find-
ings. Regarding lipid profile, Dr Jamie Gaida and colleagues 
reported that triglyceride level, triglyceride/high-density lipopro-
tein cholesterol ratio and apolipoprotein B were elevated in patients 
with AT.34 Hypertension prevalence was found to be increased in 
females in the study by Holmes and Lin, suggesting a possible rela-
tionship between blood flow circulation to the Achilles tendon and 
AT.38 However, all of these factors should be studied in a longitu-
dinal study design since it is not clear whether there is a cause–effect 
relationship.
Genetic profiling is also a major topic in AT. Since 2002, 16 
cross-sectional studies have evaluated the presence of genetic varia-
tions in AT.26 29 33 37 39 44–49 51–55 These genetic variations are linked 
to collagen structure, tendon or matrix homeostasis, apoptosis or 
inflammation pathways.8 This type of research provides more infor-
mation regarding the biological pathways of the disorder. Future 
therapy strategies could focus on targeting these pathways.
strengths and limitations
The strength of this systematic review is that we performed this 
structured analysis according to the PRISMA guidelines.82 Conse-
quently, we were able to include 10 cohort studies, whereas a 
different systematic review on this topic only included one cohort 
study.8 That recent systematic review provided an excellent over-
view of all the literature considering genetic variants in AT, but 
important publications considering non-genetic risk factors in 
AT were missing. By including these cohort studies, our methods 
provide evidence that can be used directly in a clinical setting. We 
were also able to present an overview of topics on which future 
research should focus. Despite our robust research design, there are 
also methodological limitations. First, we only selected publications 
written in the English language. Second, we were not able to pool 
data because of the heterogeneity. The strength of the associations 
could therefore only be evaluated with a best evidence synthesis and 
not with meta-analysis. Third, we chose to use a standardised set of 
criteria based on modified questions of existing quality assessment 
tools. This was recommended by Hayden et al, since no validated 
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tools are available for systematic reviews on risk factors.83 Our tool 
used strict criteria, primarily considering clinical examination as 
valid outcome measure (criterion 6). Four cohort studies did not 
meet this criterion of which three of these studies used International 
Statistical Classification of Diseases and Related Health Problems 
(ICD) codes/search terms.17 24 25 The fourth study examined only 
runners with serious symptoms.20 These approaches to case-finding 
creates a bias. Furthermore, if this criterion would not be taken 
into account, the studies would still be considered to be of high risk 
of bias based on the other criteria. Fourth, the median age of the 
included cohort studies was 21 years due to the profession of most 
of the populations investigated. This is a relatively young age, since 
the mean age to develop AT is 30–60 years, and AT is therefore 
expected to be less common in these studies.69
COnCLusIOn
There is a lack of high-quality prospective studies investigating risk 
factors for AT. We found limited evidence for nine determinants as 
risk factor for Achilles tendinopathy: a history of lower limb injury, 
season of training, calf muscle strength, gait analysis parameters, 
moderate alcohol use, fluoroquinolone antibiotic treatment and 
suboptimal renal function in a specific heart transplant population. 
Research funding agencies should prioritise research into modifi-
able determinants as these could prove useful for AT prevention and 
treatment. Quality studies will use valid clinical examination (focal 
Achilles tendon pain in relation to load with impaired load-bearing 
capacity) as outcomes, valid and reliable risk factor measurements 
and adequate statistical analysis in heterogeneous populations.
What is already known
 ► Achilles tendinopathy is considered to be an overuse injury. 
However, the exact aetiology remains unclear.
 ► The disorder is most frequently seen in runners and running 
sports in the age range from 30 years old to 60 years old.
 ► Being overweight, chronic diseases that affect tendon quality 
(diabetes, rheumatoid arthritis or hypercholesterolaemia), 
the use of fluoroquinolones or statins, a reduced plantar 
flexor strength and a reduced ankle dorsiflexion are generally 
considered to be risk factors for Achilles tendinopathy. To 
date, conclusive evidence is missing.
What are the new findings
 ► There is a lack of high-quality studies regarding risk factors 
for Achilles tendinopathy.
 ► Ten cohort studies were identified, all with a high risk of 
bias.
 ► There is limited evidence for nine determinants as risk 
factors for Achilles tendinopathy: (1) prior lower limb 
tendinopathy or fracture, (2) use of ofloxacin antibiotics, (3) 
increased time between heart transplantation and initiation 
of quinolone treatment for infectious disease, (4) moderate 
alcohol use, (5) training during cold weather, (6) decreased 
isokinetic plantar flexor strength, (7) an abnormal gait 
pattern with decreased forward progression of propulsion, 
(8) more lateral foot roll-over at the forefoot flat phase and 
(9) creatinine clearance of <60 mL/min in heart transplant 
patients.
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